Literature DB >> 22271464

Can endoscopy be avoided in the assessment of ulcerative colitis in clinical trials?

Ashwin D Dhanda1, Tom J Creed, Rosemary Greenwood, Bruce E Sands, Christopher S Probert.   

Abstract

BACKGROUND: There is no gold standard index in the measurement of ulcerative colitis (UC) disease activity in clinical trials. Mucosal healing has been described as an important clinical endpoint requiring endoscopic assessment, which is unpleasant for the patient and may hamper recruitment to trials. The aim of this study was to determine whether endoscopy is necessary in the assessment of UC disease activity and whether a noninvasive disease activity index (partial Mayo score) could be used to predict the Mayo score.
METHODS: In all, 149 subjects with moderate to severe UC enrolled in a clinical trial were assessed using total and partial Mayo scores. Histologic assessment of biopsies was performed. A regression model was constructed to predict total Mayo score from the partial Mayo score and histology score from the Mayo score. A Bland-Altman test of agreement was performed.
RESULTS: The partial Mayo score correlated closely with the total Mayo score at week 4 (rho = 0.97) and week 8 (rho = 0.98). The model to predict total from partial Mayo score showed excellent correlation (rho = 0.97) and good agreement with the total Mayo score at week 4 and the week 8 validation set (rho = 0.97) and accurately classified disease severity (kappa = 0.82). The model to predict histology score from the Mayo score correlated only moderately with the actual histology score at week 4 (rho = 0.59) and week 8 (rho = 0.36).
CONCLUSIONS: The Mayo score can be accurately predicted from the partial Mayo score. A noninvasive index can replace the Mayo score in future clinical trials.
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 22271464     DOI: 10.1002/ibd.22879

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  18 in total

1.  Long-Term Follow-Up of Patients Treated with Infliximab for Ulcerative Colitis: Predictive Factors of Response-An Observational Study.

Authors:  Orlando García-Bosch; Montserrat Aceituno; Ingrid Ordás; Josefina Etchevers; Miquel Sans; Faust Feu; Julián Panés; Elena Ricart
Journal:  Dig Dis Sci       Date:  2016-02-26       Impact factor: 3.199

Review 2.  "Mucosal healing" in ulcerative colitis: Between clinical evidence and market suggestion.

Authors:  Cristiano Pagnini; Francesca Menasci; Stefano Festa; Gianenrico Rizzatti; Gianfranco Delle Fave
Journal:  World J Gastrointest Pathophysiol       Date:  2014-05-15

Review 3.  Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid?

Authors:  Robert Battat; Parambir S Dulai; Christopher Ma; Vipul Jairath; Brian G Feagan; William J Sandborn; Reena Khanna
Journal:  Curr Treat Options Gastroenterol       Date:  2020-01-04

4.  Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis.

Authors:  Burton I Korelitz; Keith Sultan; Megha Kothari; Leo Arapos; Judy Schneider; Georgia Panagopoulos
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

5.  An optimized patient-reported ulcerative colitis disease activity measure derived from the Mayo score and the simple clinical colitis activity index.

Authors:  Meenakshi Bewtra; Colleen M Brensinger; Vesselin T Tomov; Tram B Hoang; Carly E Sokach; Corey A Siegel; James D Lewis
Journal:  Inflamm Bowel Dis       Date:  2014-06       Impact factor: 5.325

6.  Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission.

Authors:  Laura Rosenberg; Garrett O Lawlor; Talia Zenlea; Jeffrey D Goldsmith; Anne Gifford; Kenneth R Falchuk; Jacqueline L Wolf; Adam S Cheifetz; Simon C Robson; Alan C Moss
Journal:  Inflamm Bowel Dis       Date:  2013 Mar-Apr       Impact factor: 5.325

7.  Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes.

Authors:  Sasha Taleban; Kathleen O Stewart; Darrick K Li; Prashant Singh; Darrell S Pardi; Holly C Sturgeon; Vijay Yajnik; Ramnik J Xavier; Ashwin N Ananthakrishnan; Hamed Khalili
Journal:  Dig Dis Sci       Date:  2016-05-03       Impact factor: 3.199

8.  Influence of the COVID-19 Outbreak on Disease Activity and Quality of Life in Inflammatory Bowel Disease Patients.

Authors:  Chiara Conti; Ilenia Rosa; Luigia Zito; Laurino Grossi; Konstantinos Efthymakis; Matteo Neri; Piero Porcelli
Journal:  Front Psychiatry       Date:  2021-04-22       Impact factor: 4.157

9.  The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine.

Authors:  Aaron Yarlas; Mary Kaye Willian; Arpita Nag
Journal:  Qual Life Res       Date:  2021-03-02       Impact factor: 4.147

10.  Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study.

Authors:  Aaron Yarlas; Geert D'Haens; Mary Kaye Willian; Megan Teynor
Journal:  Inflamm Bowel Dis       Date:  2018-01-18       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.